Related Experiment Video

Updated: Aug 5, 2025

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
06:04

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

2.4K

[Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe?]

A I Álvaro Varela1, A Aguinaga Pérez, A Navascués Ortega

  • 1Ana Isabel Álvaro Varela, Servicio de Microbiología Clínica, Hospital Universitario de Navarra, Pamplona, Spain. ai.alvaro.varela@navarra.es.

Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|March 26, 2023
PubMed

Insights

Mycoplasma pneumoniae causes atypical pneumonia worldwide. Macrolide resistance is increasing, necessitating advanced molecular diagnostics for effective outbreak control.

Area of Science:

  • Microbiology
  • Infectious Diseases

Context:

  • Mycoplasma pneumoniae is a common cause of atypical pneumonia globally.
  • Epidemic outbreaks occur every 4-7 years, with endemic circulation between outbreaks.
  • Macrolides, tetracyclines, and fluoroquinolones are primary treatments.

Purpose:

  • To summarize the epidemiology and clinical significance of Mycoplasma pneumoniae.
  • To highlight the growing challenge of macrolide resistance.
  • To emphasize the role of advanced diagnostics in managing M. pneumoniae.

Summary:

  • Mycoplasma pneumoniae infections are prevalent worldwide, primarily affecting the respiratory tract and causing atypical pneumonia.
  • A significant increase in macrolide resistance has been observed globally since 2000, particularly in Asia, with varying frequencies in Europe.
  • Molecular and serology techniques offer high sensitivity for diagnosis and outbreak control, while macrolide resistance detection requires sequencing.

Impact:

  • Informing clinicians about current treatment challenges and diagnostic options.
  • Guiding public health strategies for Mycoplasma pneumoniae outbreak detection and management.
  • Highlighting the need for continued surveillance of antimicrobial resistance patterns.
Keywords:
Mycoplasma pneumoniaePCRmacrolidesresistance

More Related Videos

Optimized PCR-based Detection of Mycoplasma06:01

Optimized PCR-based Detection of Mycoplasma

Published on: June 20, 2011

54.1K
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.1K

Related Concept Videos

Bacterial Phylum Tenericutes01:24

Bacterial Phylum Tenericutes

The phylum Tenericutes, which includes the single class Mollicutes, comprises bacteria that lack cell walls. The term "Mollicutes" derives from the Latin word mollis, meaning "soft." These organisms are among the smallest known and are commonly referred to as mycoplasmas due to the prominence of the genus Mycoplasma, which includes well-known human pathogens. Despite their inability to stain gram-positively (a result of their lack of cell walls), mycoplasmas are phylogenetically related to the...
49
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
383
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
409